September 19, 2025Вопросы современной педиатрииOpen Access

Dupilumab Administration in the Patient with Severe Eosinophilic Esophagitis Combined with T2-Associated Diseases: Case Study

View Full Paper

Ask AI

Bookmark

Authors

SVSvetlana S. VyazankinaMinistry of Health of the Russian Federation NMNikolay N. MurashkinSechenov University SMSvetlana G. MakarovaRussian Academy of Sciences

Discussion

Member takes

Implication

Case study reveals dupilumab's effectiveness in reducing eosinophilic infiltration and symptom severity, suggesting new approaches for T2-associated conditions.

Key Points

Dupilumab significantly reduces symptoms and eosinophilic infiltration in a child with severe eosinophilic esophagitis.
Three months of dupilumab therapy resulted in dysphagia reduction and normalization of physical development indicators like HAZ and BAZ.
This observational case highlights dupilumab's potential in treating eosinophilic esophagitis refractory to standard therapies.
The therapy led to remission of atopic dermatitis and avoided the need for endoscopic esophageal dilation.

Cite This Study

Vyazankina et al. (2025) studied this question.

synapsesocial.com/papers/68d437fe713b0b5dfea77cc2 https://doi.org/10.15690/vsp.v24i4.2931

View Full Paper

Ask AI

Bookmark

Implication

Case study reveals dupilumab's effectiveness in reducing eosinophilic infiltration and symptom severity, suggesting new approaches for T2-associated conditions.

Dupilumab Administration in the Patient with Severe Eosinophilic Esophagitis Combined with T2-Associated Diseases: Case Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Dupilumab Administration in the Patient with Severe Eosinophilic Esophagitis Combined with T2-Associated Diseases: Case Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider